累及轴外中枢神经系统的霍奇金淋巴瘤:COG与EuroNet-PHL的AHOD1331、PHL-C1和PHL-C2报告
在AHOD1331及PHL-C1、PHL-C2试验的4995例患儿中,45例诊断时存在55个轴外中枢神经系统病变,总体发生率0.9%。病变从邻近软组织或骨扩展入轴外中枢神经系统空间,不直接穿透硬脑膜。2周期化疗后89.1%病变达完全代谢缓解且体积缩小>75%。
要点
- 儿童霍奇金淋巴瘤诊断时中枢神经系统累及总体发生率为0.9%。
- 82.2%患者仅有单个中枢神经系统病变,位于胸、腰或骶段脊柱。
- 2周期化疗后89.1%中枢神经系统病变达完全代谢缓解且体积缩小>75%。
核心结论
- 这是迄今报道的最大规模诊断时系统性霍奇金淋巴瘤累及中枢神经系统的队列,病变起源于周围组织、扩展入轴外中枢神经系统空间,且对其他淋巴结和结外病变反应相似。
研究设计与样本
- 队列来自儿童肿瘤学组AHOD1331及欧洲儿童霍奇金淋巴瘤网络PHL-C1和PHL-C2试验,共4995例患者,其中45例诊断时存在55个轴外中枢神经系统病变。
主要发现
- 中枢神经系统累及的总体发生率为0.9%。
- 高达82.2%的患者仅有单个中枢神经系统病变,位于胸、腰或骶段脊柱。
- 在评估队列中,霍奇金淋巴瘤未发生于中枢神经系统实质内;病变从邻近软组织或骨扩展入轴外中枢神经系统空间,从未直接穿透硬脑膜进入脑或脊髓。
- 中枢神经系统累及患者结外病变发生率是既往无中枢神经系统累及队列报告的两倍。
- 2周期化疗后,89.1%的中枢神经系统病变达完全代谢缓解且体积缩小>75%;13个(23.6%)中枢神经系统病变接受放疗,均非疾病复发部位;2个中枢神经系统病变部位发生复发,两者中期化疗反应均充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hodgkin lymphoma (HL) involving the central nervous system (CNS) is exceedingly rare. Information regarding the presentation, management, treatment, and outcome of patients with CNS HL is limited to case reports or small series. We describe 45 pediatric patients with 55 extra-axial CNS lesions at diagnosis with HL from a cohort of 4995 patients enrolled on Children's Oncology Group AHOD1331 and the European Network for Pediatric Hodgkin lymphoma C1 and C2 trials, with an overall incidence of 0.9%. Up to 82.2% of patients had a single CNS lesion in the thoracic, lumbar, or sacral spine. In the evaluated cohort, HL did not occur within the CNS parenchyma. Lesions extended into the extra-axial CNS space from adjacent soft tissue or bone and never directly infiltrated through the dura into the brain or spinal cord. Patients with CNS involvement had a twofold greater incidence of extranodal lesions than previously reported cohorts without CNS involvement. After 2 cycles of chemotherapy, 89.1% of CNS lesions demonstrated a complete metabolic response and >75% decrease in volume. Thirteen CNS lesions (23.6%) received irradiation; none were sites of disease relapse. Relapse occurred at the site of 2 lesions involving the CNS, both of which had an adequate interim response to chemotherapy. In summary, we present, to our knowledge, the largest reported cohort of systemic HL involving the CNS at diagnosis, demonstrating that these lesions originate from surrounding tissues, extend into the extra-axial CNS space, and respond similarly to other nodal and extranodal disease. The trials were registered at www.clinicaltrials.gov as #NCT02166463, #NCT00433459, and #NCT02684708.
引用
- Pabari R, McCarten K, Flerlage J, et al. Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL. Blood Adv. 2024. PMID: 39058968. doi:10.1182/bloodadvances.2023012346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。